P502 HIV prevalence and behavior study among pregnant women in Georgia

of late toxicity was similar between the two groups. The complete response rate was 87.7% and 86.7% for groups I and II, respectively. Five-year overall and cancer-specific survival rates were, respectively, 49.7% and 61.1% in group I, and 57.4% and 68.8% in group II, indicating no significant survival benefit with concurrent chemoradiotherapy. Performance status, comorbidity index and tumor size were significant prognostic factors for overall survival, whereas tumor size was the only significant prognostic factor for cancer-specific survival. Conclusions: This analysis showed no benefit of concurrent chemoradiotherapy with respect to overall and cancer-specific survival in elderly women. A prospective study is needed to determine the role of concurrent chemoradiotherapy in this population.